Literature DB >> 20038937

Engineering cell-permeable protein.

Bernhard Münst1, Christoph Patsch, Frank Edenhofer.   

Abstract

The protein transduction technique enables the direct delivery of biologically active material into mammalian cells [for review see (1,2)]. For this one can make use of the translocating ability of so-called cell penetrating peptides (CPPs), also designated as protein transduction domains (PTDs). The TAT-CPP derived from the human immunodeficiency virus type 1 (HIV-1) Tat (trans-activator of transcription) protein has been widely used. The positively charged TAT promotes cell permeability thereby overcoming the barriers of the cellular membrane by endocytosis or/and direct membrane penetration(2). In combination with a nuclear localization signal (NLS) fusion proteins are able to enter the nucleus exhibiting functionality. Our video presentation demonstrates, as an exemplification for the engineering of cell-permeable proteins, the construction, production and application of a cell-permeable version of the DNA-modifying enzyme Cre. Cre is a site-specific recombinase that is able to recognize and recombine 34 base pair loxP sites in mammalian cells in vitro and in vivo. Therefore the Cre/loxP system is widely used to conditionally induce mutations in the genome of living cells(3,4). The delivery of active Cre recombinase to cells, however, represents a limitation. We describe the pSESAME vector system, which allows a direct insertion of the gene-of-interest and provides a platform to rapidly clone different domains and tags used within the vector in a convenient and standardized manner. Rearranging of the different tags has been shown to modify the biochemical properties of the fusion proteins providing a possibility to achieve higher yield and better solubility. We demonstrate how to express and purify recombinant cell-permeant proteins in and from E. coli. The functionality of the recombinant Cre protein is finally validated in cell culture by assessing its intracellular recombinase activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038937      PMCID: PMC3149971          DOI: 10.3791/1627

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


Protocol

Construction of expression vector and expression:

The pSESAME-Cre expression vector was constructed by inserting a Cre-encoding fragment into pSESAME via AvrII and NheI restriction sites using standard cloning methods. pSESAME encodes a fusion protein consisting of a histidine-tag, TAT-domain, NLS sequence and Cre, abbreviated HTNCre. For expression of HTNCre the pSESAME-Cre was transformed into TUNER (DE3) pLacI and used to prepare a glycerol stock. An over-night culture was inoculated using a pipet tip coated with transformed bacteria from the glycerol stock. The over-night culture consisted of LB media supplemented with 0.5% glucose [v/v] and carbenicillin at a final concentration of 50 μg/mL and was allowed to grow at 37°C for 16 hours. Next day the densely grown over-night culture was used to inoculate the expression culture at a ratio of 1 to 40 and was put in an incubator at 37°C. Expression culture consisted of TB media supplemented with 0.5% glucose [v/v] and ampicillin at a final concentration of 100 μg/mL. At an OD595 of 1.5 the expression culture was induced with 0.5 mM IPTG for 1 h. Subsequently bacteria were collected by centrifugation at 5000 rpm for 10 minutes in a SLA3000 rotor. Bacteria pellets were stored at minus 20°C until purification. Frozen bacteria pellets were resuspended in 10 mL lysis buffer per liter flask culture for 15 minutes at room temperature. Suspension was then incubated with 1 mg/mL lysozyme for additional 15 minutes while mixing at room temperature. 25 U/mL benzonase was added afterwards and incubated while mixing for 15 minutes at room temperature. After sonification on ice for 1.5 min with 0.5 s pulses at 45% of the power, 1 mL cold tartaric salt buffer (TSB) per mL suspension was carefully added while mixing and incubated for 5 min on ice. SDS-PAGE sample of lysate fraction (L) was taken. Cleared lysate was obtained by centrifugation at 4°C for 30 min at 30,000g. SDS-PAGE samples of soluble (S) and insoluble fractions (I) were taken. The supernatant was transferred into fresh 50 mL falcon tubes and was then gently mixed for 1 h at 4°C with 2 mL of 50% Ni-NTA slurry per liter of initial expression culture. The suspension was packed into a gravity flow EconoPac column (SDS-PAGE sample of flow-through fraction (FT) was taken) and washed twice with 5 bed-volumes of washing buffer. SDS-PAGE samples of both washing fractions (W1 & W2) were collected. HTNCre-containing fractions were eluted with 3 bed-volumes of elution buffer and sample of eluate fraction (E) for SDS-PAGE analysis was taken. Imidazole was removed by dialyzing elution fraction against high salt buffer twice. The protein solution was further concentrated by dialyzing against glycerol buffer twice. In all dialysis steps the ratio of buffer to sample was at least 50. This procedure resulted in a glycerol stock solution containing HTNCre at a usual concentration between 200 and 450 μM, i.e. 1 liter of expression culture will result in ~12 mg of protein. Sample of glycerol stock (GS) for SDS-PAGE analysis was collected. HTNCre stock solution can be stored at minus 20°C.

Purification of cell-permeable protein:

Figure 1: SDS-PAGE analysis of the samples collected during the purification process of Cre recombinase. Induction of Cre expression is indicated by dominant band in lysate fraction. Although a part of the protein is insoluble the Cre protein can be further enriched as seen in eluate and glycerol stock fractions. L: Lysate, I: Insoluble, S: Supernatant, FT: Flow-through, W: Washing, E: Eluate, GS: Gylcerol Stock. Please click here to see a larger version of figure 1. ES cells carrying a conditional β-Galactosidase reporter5 construct were seeded as single cells using TrypLE™ Express for dissociation of adherent cells. After 4 to 6 hours the cells had re-attached and the medium was removed. Subsequently ES cells were incubated with HTNCre-containing medium for 16 hours. An appropriate amount of HTNCre protein (corresponding to 10 μM) out of the glycerol stock was diluted into ES medium and subsequently sterile filtrated (0.22 μm). After protein transduction medium was changed back to normal growth medium. After two days cells were washed with PBS and fixed with 4% Paraformaldehyde (PFA) for 10 minutes. Two additional washing steps with PBS were executed before X-Gal staining was performed. Fixed cells were covered with a layer of X-Gal staining solution6 and incubated over night at 37°C.

Representative Results:

Next day X-Gal staining solution was aspired and the cells were covered with a layer of PBS for microscopy analysis. 80 to 100% of recombined cells could be observed within the murine ES cells judged by β-Galactosidase activity.

Discussion

During the purification process of the Cre fusion protein it is important not to omit the addition of ice cold TBS buffer prior to centrifugation. Otherwise Cre recombinase tends to precipitate within the glycerol buffer. If the eluate fraction appears to become turbid due to the high concentration of fusion protein additional elution buffer should be added until the solution has cleared again. The application of 10 μM of Cre fusion protein typically results in a recombination efficiency of 80 to 100%. Fetal Calf Serum (FCS) being a major component of ES cell medium strongly inhibits protein transduction. Therefore high concentration of Cre recombinase had to be used. When working in serum-free conditions less protein (0.5 - 2 μM) can be used to achieve similar recombination efficiencies. With the pSESAME vector system at hand one can apply the technique of protein transduction to other proteins including transcription factors such as Oct4 and Sox27 and Scl/Tal18.
  8 in total

Review 1.  Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice.

Authors:  Catherine S Branda; Susan M Dymecki
Journal:  Dev Cell       Date:  2004-01       Impact factor: 12.270

2.  Site-specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase.

Authors:  Lars Nolden; Frank Edenhofer; Simone Haupt; Philipp Koch; F Thomas Wunderlich; Henrike Siemen; Oliver Brüstle
Journal:  Nat Methods       Date:  2006-06       Impact factor: 28.547

Review 3.  TAT transduction: the molecular mechanism and therapeutic prospects.

Authors:  Jacob M Gump; Steven F Dowdy
Journal:  Trends Mol Med       Date:  2007-10       Impact factor: 11.951

4.  Enhanced purification of cell-permeant Cre and germline transmission after transduction into mouse embryonic stem cells.

Authors:  Michael Peitz; Richard Jäger; Christoph Patsch; Andrea Jäger; Angela Egert; Hubert Schorle; Frank Edenhofer
Journal:  Genesis       Date:  2007-08       Impact factor: 2.487

Review 5.  Protein transduction revisited: novel insights into the mechanism underlying intracellular delivery of proteins.

Authors:  Frank Edenhofer
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

6.  Generation of transducible versions of transcription factors Oct4 and Sox2.

Authors:  Manal Bosnali; Frank Edenhofer
Journal:  Biol Chem       Date:  2008-07       Impact factor: 3.915

7.  Inducible site-directed recombination in mouse embryonic stem cells.

Authors:  Y Zhang; C Riesterer; A M Ayrall; F Sablitzky; T D Littlewood; M Reth
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

8.  Runx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver.

Authors:  Josette-Renée Landry; Sarah Kinston; Kathy Knezevic; Marella F T R de Bruijn; Nicola Wilson; Wade T Nottingham; Michael Peitz; Frank Edenhofer; John E Pimanda; Katrin Ottersbach; Berthold Göttgens
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

  8 in total
  7 in total

1.  Non-genetic modulation of Notch activity by artificial delivery of Notch intracellular domain into neural stem cells.

Authors:  Simone Haupt; Lodovica Borghese; Oliver Brüstle; Frank Edenhofer
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

2.  A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins.

Authors:  Pierre Chapdelaine; Zoé Coulombe; Amina Chikh; Catherine Gérard; Jacques P Tremblay
Journal:  Mol Ther Nucleic Acids       Date:  2013-09-03       Impact factor: 10.183

3.  Dual fluorescent reporter pig for Cre recombination: transgene placement at the ROSA26 locus.

Authors:  Shun Li; Tatiana Flisikowska; Mayuko Kurome; Valeri Zakhartchenko; Barbara Kessler; Dieter Saur; Alexander Kind; Eckhard Wolf; Krzysztof Flisikowski; Angelika Schnieke
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

4.  Evidence for a Strong Relationship between the Cytotoxicity and Intracellular Location of β-Amyloid.

Authors:  Md Aminul Haque; Md Selim Hossain; Tahmina Bilkis; Md Imamul Islam; Il-Seon Park
Journal:  Life (Basel)       Date:  2022-04-13

5.  Cell reprogramming requires silencing of a core subset of polycomb targets.

Authors:  Giulia Fragola; Pierre-Luc Germain; Pasquale Laise; Alessandro Cuomo; Alessandro Blasimme; Fridolin Gross; Elena Signaroldi; Gabriele Bucci; Cesar Sommer; Giancarlo Pruneri; Giovanni Mazzarol; Tiziana Bonaldi; Gustavo Mostoslavsky; Stefano Casola; Giuseppe Testa
Journal:  PLoS Genet       Date:  2013-02-28       Impact factor: 5.917

6.  Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs.

Authors:  Simon Leuchs; Anja Saalfrank; Claudia Merkl; Tatiana Flisikowska; Marlene Edlinger; Marina Durkovic; Nousin Rezaei; Mayuko Kurome; Valeri Zakhartchenko; Barbara Kessler; Krzysztof Flisikowski; Alexander Kind; Eckhard Wolf; Angelika Schnieke
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

7.  A porcine model of osteosarcoma.

Authors:  A Saalfrank; K-P Janssen; M Ravon; K Flisikowski; S Eser; K Steiger; T Flisikowska; P Müller-Fliedner; É Schulze; C Brönner; A Gnann; E Kappe; B Böhm; B Schade; U Certa; D Saur; I Esposito; A Kind; A Schnieke
Journal:  Oncogenesis       Date:  2016-03-14       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.